BioStock: Pila Pharma initiates toxicological studies

Malmö company Pila Pharma is in full swing with preparations for a phase IIb study with the drug candidate XEN-D0501. But before the study can initiated, the company needs to conduct a three-month preclinical toxicological study. The company has now announced that the toxicological study has started. BioStock contacted Pila Pharma’s CEO Dorte X Gram to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/07/pila-pharma-initiates-toxicological-studies/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se